How Effective Are the NHP Regulations? A 2026 Evidence Review

"How effective are the NHP Regulations?" is usually asked rhetorically, by someone who has already decided the answer. Industry says the rules are heavy-handed. Consumer advocates say they are toothless. Both cannot be right, and as it happens, both are partly right.

There is a better way to answer the question than trading opinions. Health Canada publishes its own inspection results, its own audit responses and its own regulatory impact analyses. Those documents are unusually candid. Read together, they show a framework that is comprehensive in what it requires and weak in what it verifies, and a regulator that has said so itself.

This article assesses the Natural Health Products Regulations against the evidence Health Canada has published, current to July 2026. It is written for licence holders who need to know where the real risk sits, which is not always where the noise is.

Executive Summary

• The Natural Health Products Regulations (SOR/2003-196) came into force on January 1, 2004 and cover product licensing, site licensing, good manufacturing practices, adverse reaction reporting and labelling.
• Health Canada's 2021 to 2022 pilot inspection programme conducted 36 inspections covering about 4% of companies holding active NHP site licences. Compliance issues ranging in severity were found at all the companies inspected.
• Problems were significant enough at 42% of companies inspected, 15 of the 36 inspections, for Health Canada to inform companies about potential or immediate suspensions of site or product licences.
• The 2022 labelling reforms, including the Product Facts table, were pushed out by ministerial order. The effective compliance date is now June 22, 2028, six years after the rules were made.
• Vanessa's Law was extended to NHPs in June 2023, but the powers requiring regulations, including terms and conditions on authorizations and mandatory tests or studies, are still not in force three years later.
• GUI-0158 version 4.0 came into force on March 4, 2026, the first substantive refresh of NHP GMP guidance since December 2015.
• For licence holders the practical conclusion is straightforward: inspection is now more likely than at any point since 2004, and the historical base rate of finding nothing is effectively zero.

What the NHP Regulations Actually Require

What it is: the Natural Health Products Regulations, SOR/2003-196, made under section 30(1) of the Food and Drugs Act. They came into force on January 1, 2004 and are the complete regulatory code for vitamins, minerals, herbal remedies, homeopathic medicines, probiotics and similar products sold in Canada.

Why it matters: NHPs are legally drugs under the Food and Drugs Act. What the Regulations do is carve them out of the Food and Drug Regulations and apply a bespoke, lighter regime instead. That carve-out is the origin of most arguments about effectiveness. The question is not whether NHPs are regulated. It is whether the bespoke regime is calibrated correctly.

The pattern in that final column is the finding of this article. The Regulations are strong where they gate entry and weak where they require ongoing verification. That is not an accident of drafting. It is a resourcing and design choice, and Health Canada has now acknowledged it in print.

The Inspection Evidence: What Health Canada Found When It Finally Looked

What it is: for roughly the first seventeen years of the NHP framework, Health Canada had no proactive inspection programme for natural health product sites. Between March 2021 and March 2022 it ran a pilot: 36 inspections, 18 manufacturers and 18 importers, in Quebec, Ontario and British Columbia, averaging seven days each. That covered about 4% of all companies with active NHP site licences in Canada.

Why it matters: this is the only systematic dataset on whether NHP licence holders actually comply. It is the closest thing to an answer to the title of this article, and it comes from the regulator itself rather than from a critic.

One caveat matters for honesty about what these numbers prove. The pilot used risk-based selection, not random sampling. Health Canada chose sites it had reason to look at, so 42% is not a clean estimate of the national non-compliance rate and should not be presented as one.

That caveat is weaker than it first appears. The all companies finding is not a rate, it is a clean sweep, and risk selection does not explain why not one site in 36 was clean. The pilot was also not the first attempt: from 2017 to 2019 Health Canada ran three proactive compliance monitoring projects, and about half of the companies had issues serious enough for regulatory action. Two independent exercises, five years apart, same conclusion.

What happened to the 15 companies is instructive. Twelve submitted adequate corrective and preventive action plans, one of which let its site licence expire rather than remediate. Two progressed to notices of suspension. The standard path out of a serious finding is a CAPA plan, not a suspension. That is a workable posture, but only if someone inspects in the first place.

Where the deficiencies clustered

Health Canada published the categories of deficiency but not the count per category, so treat the following as the areas that came up rather than a ranked list: specifications (section 44), premises, equipment, personnel, sanitation, operations, recall system, quality assurance (section 51), stability (section 52), records for manufacturers and importers including retention, lot samples (section 61) and recall reporting (section 62).

The most revealing detail is what companies said afterwards. Health Canada reported that the requirements under sections 44, 51 and 52, specifications, quality assurance and stability, were still unclear to some companies after inspection. Not before. After. When a company has been inspected, told it is deficient, and still cannot work out what compliance looks like, the failure is at least partly in the guidance. That is the strongest available argument that the NHP Regulations underperform, and it is Health Canada making it.

An interim inspection programme was stood up in October 2022, described as an initial step to creating a permanent programme. As of Health Canada's current published position, the permanent proactive inspection programme is still being developed while inspection activities continue. Four years is a long interim.

The Labelling Reforms: Made in 2022, Due in 2028

What it is: SOR/2022-146, registered June 21, 2022, introduced four changes to NHP labels: a Product Facts table, clear and prominent display of label text, labelling of food allergens, gluten, added sulphites and aspartame, and modernized contact information. These were the most significant consumer-facing reforms since 2004.

Why it matters: they have not taken effect. A ministerial order, SOR/2025-94, registered March 7, 2025 and made under section 30.05 of the Food and Drugs Act, came into force on June 21, 2025, the very day the labelling requirements were due to bite, and is repealed on June 21, 2028. The practical result, in Health Canada's own words, is that products have until June 22, 2028 to comply with the new labelling requirements.

There is a second limb worth understanding. NHPs authorized on or after June 21, 2025 are exempt from the new labelling provisions provided the product is labelled in accordance with the Regulations as they read immediately before June 21, 2025. New products can still enter the market under the old label rules.

What to do: do not treat 2028 as far away, and do not assume it is the final answer. But the more interesting point is why the delay happened, because Health Canada's stated reasons are an unusually direct self-assessment.

The regulatory impact analysis says the available guidance materials are not effective in supporting implementation. It records that industry could not fit all required information on the label, and that compliance risked compromising readability. Most striking, Health Canada conceded the safety cost of its own decision: suppliers of newly licensed NHPs would be exempted from prominently displaying a safety statement regarding things like allergens, gluten, added sulphites and aspartame, and thus the previously identified risk will continue. It then acknowledged it could not quantify or monetize the analysis without the necessary information.

Sit with that. A safety rule aimed at allergen disclosure was made in 2022, delayed to 2028, and the reason given was that the regulator's own guidance was not usable. The risk it was designed to address continues in the meantime, by admission. In a market where public opinion research published in 2024 reports that more than 73% of people in Canada used NHPs, with 57% of those reporting daily use, that is a meaningful gap between intent and effect. It is not that the rules are wrong. It is that rule-making and implementation capacity are not aligned.

Enforcement Powers: Granted in 2023, Half of Them Still Unusable

What it is: in June 2023 the Government of Canada passed legislation amending the Food and Drugs Act to extend the authorities under the Protecting Canadians from Unsafe Drugs Act, known as Vanessa's Law, to natural health products. This was the most significant strengthening of NHP oversight since the Regulations were made.

Why it matters: before that change, Health Canada could not order a recall of a natural health product. It could ask. The extension closed a genuine hole. But only some of the powers are actually live.

What to do: note which four powers are missing, because they are the ones that would let Health Canada compel evidence rather than react to harm. Terms and conditions, mandatory tests or studies, and reassessment of risks and benefits are the tools a regulator uses to interrogate a product it is unsure about. Health Canada's published commitment is only that it will consult with stakeholders to determine when and how these regulations would come into force. Three years on, no such regulations have been made.

The enforcement policy has a related gap. POL-0044, issued on August 29, 2014, remains Health Canada's current published policy for natural health products. It predates the 2023 extension of Vanessa's Law by nine years and still describes a posture in which requesting a stop sale is usually the minimum action taken. That is a request-first framework describing a regulator that now has mandatory recall power. The policy has not caught up with the statute.

The legislative picture is not settled

Any assessment also has to account for an active attempt to reverse course. Bill C-368 would have removed natural health products from the therapeutic products regime. It passed second reading in May 2024 by 171 to 146 and died at report stage when the session ended. Its successor, Bill C-224, sponsored by the same member, received first reading on September 18, 2025, was agreed to at second reading on March 10, 2026, and is now at consideration in committee before the Standing Committee on Health. How effective the NHP Regulations are is, right now, also a live question in Parliament about how much regulation they should contain at all.

The Regulator's Own Verdict

In 2021 the Commissioner of the Environment and Sustainable Development completed an audit of Health Canada's NHP programme, covering the 2019 and 2020 period, and made five recommendations. Health Canada's own summary of the findings is that the audit identified the need for increased oversight of the quality of NHPs, greater monitoring of labels and advertising, improved product labelling, a risk-based inspection programme, and strengthened tools for compliance and enforcement. Health Canada accepted all audit recommendations and committed to addressing them.

Line those five up against the evidence above. Improved product labelling was legislated in 2022 and postponed to 2028. A risk-based inspection programme reached pilot in 2022 and is still described as under development. Strengthened compliance and enforcement tools arrived in 2023 but four of them cannot be used. Five years after accepting all five recommendations, none is closed.

The internal assessment is blunter. Health Canada's 2025 report on red tape reduction states that the Natural Health Product Regulations apply to a range of NHPs, with varying risk levels, yet all are subject to the same rules, and that the current approach results in oversight that is disproportionate to both risk and uncertainty, while also creating unnecessary burden for industry. That sentence is the answer to this article's title, written by the regulator. A one size fits all regime applied across wildly different risk levels is simultaneously too heavy for a vitamin C tablet and too light for a concentrated botanical extract with real pharmacological activity. Industry and consumer advocates are both right, about different products.

The proposed fix is a simple registration process for certain NHPs and natural product derivatives, along with flexible risk-based monitoring, more flexible labelling requirements and reduced authorization requirements. The timeline is the problem. Health Canada classifies this as long-term, to be completed in two-plus years, and anticipates publishing a regulatory proposal in Canada Gazette, Part I for consultation within three years.

What Changed in 2026: GUI-0158 Version 4.0

What it is: Health Canada's good manufacturing practices guidance for natural health products, GUI-0158, version 4.0. It was published on September 4, 2025 and came into force on March 4, 2026, replacing version 3.0.

Why it matters: version 3.0 dated from December 1, 2015. This is the first refresh in more than nine years, and it lands directly on the problem the pilot identified. Health Canada says the guidance is presented in a more user-friendly format that follows the order of the regulations under Part 3, with additional and clearer guidance including more clarity on importer-related activities.

What to do: read version 4.0 as a direct response to the finding that sections 44, 51 and 52 remained unclear to companies even after inspection. If your quality system was built against version 3.0, it was built against guidance that Health Canada's own evaluation suggests was not doing its job. Our GUI-0158 version 4.0 compliance checklist and our analysis of how GUI-0158 and the end of FSRNs reshape site licence compliance set out what to change.

Compliance Checklist: Where the Evidence Says Your Risk Actually Is

This checklist is built from the deficiency categories Health Canada published from its pilot, not from a generic GMP template. These are the areas inspectors actually wrote up.

• Specifications, section 44. Confirm every finished product and raw material has a written specification, that test methods are stated, and that results are compared against the specification before release. This was named as still unclear to companies after inspection. Treat it as your highest risk area.
• Quality assurance, section 51. Confirm you have a named person responsible for quality assurance, with defined authority, and documented evidence that each lot was assessed and released by that person.
• Stability, section 52. Confirm the expiry date on every label is supported by stability data you can produce. An expiry date with no underlying study is a common and indefensible finding.
• Recall system, sections 62 and related. Confirm a written recall procedure exists, that it has been tested by mock recall, and that you can reconcile distribution records to lot in a defined time.
• Lot samples, section 61. Confirm samples are retained for the required period and are actually retrievable.
• Importer records. Importers were half the pilot population and importer-related activities are singled out in GUI-0158 version 4.0 as needing clarity. If you import, assume you are in scope and that your foreign site evidence will be examined.
• Premises, equipment, personnel, sanitation and operations. The conventional GMP core. All appeared in the pilot findings.
• Labelling readiness for June 22, 2028. Begin Product Facts table design now. Health Canada's stated reason for the delay was that industry could not fit the information on the label. That constraint has not gone away, it has been deferred.
• Gap assessment against GUI-0158 version 4.0 rather than version 3.0. The guidance changed on March 4, 2026.

Common Mistakes

1. Reading light enforcement history as low risk. The absence of inspection for seventeen years was a capacity gap, not a policy of leniency. The pilot found issues at every company it visited, and the interim programme has been running since October 2022.

2. Treating the June 2025 labelling date as cancelled. It was not cancelled, it was moved to June 22, 2028 by an order that is itself repealed on June 21, 2028. The requirement is intact.

3. Assuming the new labelling exemption applies to existing products the same way. Products authorized on or after June 21, 2025 are exempt only if labelled in accordance with the Regulations as they read immediately before that date. It is a conditional exemption, not a blanket one.

4. Believing Health Canada still needs your cooperation to recall. The power to order a recall has been in force since 2023. POL-0044's request-first language dates from 2014 and does not reflect the current statute.

5. Building a quality system against GUI-0158 version 3.0. It was replaced on March 4, 2026, after more than nine years in force.

6. Waiting for the red tape reform. It is a proposal for Canada Gazette, Part I consultation within three years, on a two-plus year completion horizon. It is not a reason to defer anything.

7. Confusing a site licence with verified GMP compliance. A site licence has historically been granted largely on attestation. Holding one is not evidence that an inspection would go well, and the pilot data suggests strongly that it would not.

8. Assuming NHPs are not drugs. They are drugs under the Food and Drugs Act. The Regulations carve them out of the Food and Drug Regulations, but the statutory character, and the penalties, come from drug law.

Frequently Asked Questions

Are the NHP Regulations effective?

Partly. They are effective at controlling market entry, since no natural health product can be sold lawfully without a product licence and an NPN or DIN-HM. They are considerably less effective at verifying ongoing compliance. Health Canada's 2021 to 2022 pilot inspection programme found compliance issues at all 36 companies it inspected, and problems serious enough to raise potential licence suspension at 42% of them. Health Canada has also stated that its current approach produces oversight that is disproportionate to both risk and uncertainty.

Does Health Canada actually inspect natural health product sites?

Yes, but not many. A pilot programme ran 36 inspections between March 2021 and March 2022, covering about 4% of companies with active NHP site licences. An interim inspection programme was established in October 2022 and Health Canada continues to conduct inspection activities while it develops a permanent proactive inspection programme. For the first seventeen years of the framework there was no proactive site inspection programme at all.

When do the new NHP labelling requirements come into force?

June 22, 2028. The requirements were made by SOR/2022-146 in June 2022 with an original compliance date of June 21, 2025, but a ministerial order, SOR/2025-94, exempted natural health products from those provisions. That order is repealed on June 21, 2028, which makes June 22, 2028 the effective compliance date. Products authorized on or after June 21, 2025 are exempt in the meantime provided they are labelled in accordance with the Regulations as they read immediately before that date.

Why were the NHP labelling rules delayed?

Health Canada's regulatory impact analysis states that the available guidance materials were not effective in supporting implementation, that industry could not fit all required information on the label, and that compliance risked compromising readability. Health Canada also acknowledged that the exemption means the previously identified risk relating to allergens, gluten, added sulphites and aspartame will continue, and that it could not quantify the analysis without further information.

Can Health Canada order a recall of a natural health product?

Yes. Legislation passed in June 2023 extended the authorities under Vanessa's Law to natural health products, including the power to order a recall, require a label change, impose higher fines and penalties, and order production of information. Four other powers, including adding terms and conditions to authorizations and requiring tests or studies, still require enabling regulations and are not yet in force.

Are there fees for natural health product licences in Canada?

No. Health Canada consulted on a cost recovery proposal in 2023 and published significantly revised fees for consultation in 2024, but no Fees Order was ever made. Health Canada states that it currently relies solely on public funding to fund the regulatory services it provides to industry, and that it will revisit the cost recovery proposal once its red tape reduction programme adjustments have been made.

Is the NHP framework about to be repealed?

There is an active private member's bill. Bill C-368, which would have removed natural health products from the therapeutic products regime, passed second reading in May 2024 by 171 to 146 and died at report stage. Its successor, Bill C-224, was agreed to at second reading on March 10, 2026 and is at consideration in committee. Nothing has changed in law yet, but the direction of travel is contested and worth monitoring.

How MFLRC Can Help

The uncomfortable implication of Health Canada's pilot data is that a company holding a valid site licence, selling licensed products and believing itself compliant is exactly the profile that generated 36 out of 36 findings. Confidence is not evidence.

MFLRC helps natural health product companies find those gaps before an inspector does. Our audit services include mock inspections and gap assessments run against GUI-0158 version 4.0 and the specific deficiency categories from Health Canada's published findings, with CAPA plans of the kind that resolved twelve of the fifteen serious cases in the pilot. Our quality assurance support builds the specifications, stability programmes and quality assurance structures that sections 44, 51 and 52 require, the three areas companies told Health Canada were still unclear even after being inspected. Our regulatory affairs, licensing and import and export services cover product and site licensing, amendments and importer obligations.

For related reading, see our guides on NHP compliance in Canada, the GUI-0158 version 4.0 requirements, Health Canada's plan to simplify NHP licensing and labelling compliance in Canada. To test your readiness directly, work through our 25-point Health Canada GMP self-assessment. Full details of our work in this sector are on the natural health products market page.

Need to know whether your site would survive an inspection? Contact MFLRC for a gap assessment tailored to your products and processes.

Conclusion

The NHP Regulations are effective at the front door and thin everywhere else. Pre-market licensing works: nothing reaches the shelf without review. Beyond that, the framework has depended for two decades on companies doing what they attested they would do, with almost no verification. When Health Canada finally checked, it found compliance issues at every company it inspected.

The most telling evidence is not outside criticism. It is the regulator's own record: five audit recommendations accepted in 2021 and none closed; a safety labelling rule made in 2022 and postponed to 2028 because the supporting guidance was not usable; enforcement powers granted in 2023 with four still waiting on regulations; an enforcement policy from 2014 that the statute has since superseded; and a GMP guide that went nine years without a refresh while companies said they did not understand three of its core requirements.

None of that is a reason for complacency. It is the opposite. The direction is clear even if the pace is slow: GUI-0158 version 4.0 is in force, inspection activity is continuing and expanding, and mandatory recall power now exists. The gap between a paper regime and an enforced one is closing, and the companies most exposed are the ones who built their quality systems around the assumption that nobody would ever look.

Sources and References

• Natural Health Products Regulations (SOR/2003-196), Justice Laws Website (structure, Parts 1 to 5, sections cited throughout)
• Health Canada, Natural health products inspection programme (the 42% figure, 15 of 36 inspections, interim programme from October 2022)
• Health Canada, Natural health products good manufacturing practices pilot programme evaluation (36 inspections, 4% of site licence holders, issues at all companies inspected, deficiency categories, sections 44, 51 and 52 unclear after inspection, CAPA outcomes, the 2017 to 2019 projects)
• Health Canada, Improved labelling for natural health products (June 22, 2028 compliance date, conditional exemption for products authorized on or after June 21, 2025)
• SOR/2025-94, Canada Gazette, Part II, March 26, 2025 (the exemption order, repeal on June 21, 2028, and the regulatory impact analysis statements on guidance and continuing risk)
• Health Canada, Vanessa's Law and natural health products (June 2023 extension, powers in force and powers requiring regulations)
• Health Canada, Natural health products regulation overview (2021 Commissioner of the Environment and Sustainable Development audit findings and Health Canada's acceptance of all recommendations)
• Health Canada, Guide to good manufacturing practices for natural health products (GUI-0158) (version 4.0, published September 4, 2025, in force March 4, 2026, replacing version 3.0)
• Health Canada, Compliance and enforcement policy for natural health products (POL-0044) (issued August 29, 2014, stop sale as minimum action, NHPR in force January 1, 2004, NPN and DIN-HM)
• Health Canada, Cost recovery for natural health products (no fees in force, sole reliance on public funding, proposal parked pending red tape reduction)
• Health Canada, Report on red tape reduction (oversight disproportionate to risk and uncertainty, proposed registration pathway, two-plus year horizon)
• Parliament of Canada, Bill C-368 (44th Parliament) and Bill C-224 (45th Parliament) (legislative status)